Recent Release | 13 Jul 2020

Trade and transport margins in pharmaceuticals and other R&D-intensive industries

trade-and-transport-margins-in-pharmaceuticals-and-other-r-and-d-intensive-industries-300px

Spending for prescription and over-the-counter pharmaceutical products totaled $413 billion in 2012 according to the Bureau of Economic Analysis’ (BEA) trade and transports margin data. Just over half of this spending (52%) accrued to the pharmaceutical companies that produced the medicines, while the remainder was divided between transport and wholesale margins (21%) and retail margins (26%).

Compared to other research and development (R&D)-intensive manufacturing industries with significant consumer sales, the pharmaceutical and medicines manufacturing industry ranks second in terms of R&D intensity behind communications equipment, and receives the second lowest producers’ share of total spending after other miscellaneous manufacturing. Thus, the pharmaceutical industry is unique among manufacturing industries in that it devotes a large share of its revenue to R&D, despite receiving a considerably smaller share of total spending.

Read the report

You may be interested in

Aerial view of Singapore business district and city at twilight

Post

Sneak preview: our new Asia Real Estate Service

The new Asia Real Estate Economics Service helps companies understand the implications of macroeconomic, geopolitical, financial and climate change on private and public real estate performance in Asia. The first globally consistent and independent set of real estate forecasts, the service offers regular analysis and commentary from our highly experienced team of real estate economists.

Find Out More

Post

Oxford Economics Launches Global Risk Service

Oxford Economics launches our Global Risk Service, a suite of data-driven and forward-looking tools that measure macro-economic and financial crises risks in 166 countries.

Find Out More
George street, Sydney

Post

Australia’s CAPEX falters in Q1, with cost inflation to test activity

Private new capital expenditure fell 0.3% q/q in Q1 2022, led lower by a fall in buildings and structures investment. The weak result is in part due to the impact of Omicron on labour availability, and the postponement of construction activity in flood affected areas. Machinery & equipment volumes rose in the quarter.

Find Out More